These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28490259)

  • 21. The importance of model inputs and assumptions in conducting health technology assessments of novel drugs.
    Philipson T; MacEwan JP
    J Med Econ; 2017 Oct; 20(10):1107-1109. PubMed ID: 28737052
    [No Abstract]   [Full Text] [Related]  

  • 22. Does NICE apply the rule of rescue in its approach to highly specialised technologies?
    Charlton V
    J Med Ethics; 2022 Feb; 48(2):118-125. PubMed ID: 33685978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The normative grounds for NICE decision-making: a narrative cross-disciplinary review of empirical studies.
    Charlton V
    Health Econ Policy Law; 2022 Oct; 17(4):444-470. PubMed ID: 35293306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective value-based assessment of new health care technologies and practices.
    Girod CS; Axene DV
    Manag Care; 2000 Aug; 9(8):38-40, 43-7. PubMed ID: 11186514
    [No Abstract]   [Full Text] [Related]  

  • 25. Can the NICE "end-of-life premium" be given a coherent ethical justification?
    Cookson R
    J Health Polit Policy Law; 2013 Dec; 38(6):1129-48. PubMed ID: 23974470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis.
    Devlin N; Parkin D
    Health Econ; 2004 May; 13(5):437-52. PubMed ID: 15127424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NICE's social value judgements about equity in health and health care.
    Shah KK; Cookson R; Culyer AJ; Littlejohns P
    Health Econ Policy Law; 2013 Apr; 8(2):145-65. PubMed ID: 22717361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Valuing health States for use in cost-effectiveness analysis.
    Brazier J
    Pharmacoeconomics; 2008; 26(9):769-79. PubMed ID: 18767897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].
    Lakdawalla DN; Doshi JA; Garrison LP; Phelps CE; Basu A; Danzon PM
    Value Health; 2018 Feb; 21(2):131-139. PubMed ID: 29477390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Health technology assessment (HTA). Developments in healthcare and potential for radiology].
    Gizewski ER; Forsting M; Krombach GA; Schöffski O
    Radiologe; 2014 Jun; 54(6):589-98. PubMed ID: 24844855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients?
    Claxton K; Sculpher M; Palmer S; Culyer AJ
    Health Econ; 2015 Jan; 24(1):1-7. PubMed ID: 25488707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determining Value in Health Technology Assessment: Stay the Course or Tack Away?
    Caro JJ; Brazier JE; Karnon J; Kolominsky-Rabas P; McGuire AJ; Nord E; Schlander M
    Pharmacoeconomics; 2019 Mar; 37(3):293-299. PubMed ID: 30414074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reflections on NICE's Uptake of New Methods: Past, Present, and the 2020 Review.
    Boysen M; Watson I
    Pharmacoeconomics; 2020 Mar; 38(3):243-245. PubMed ID: 32016771
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical Guidelines: A NICE Way to Introduce Cost-Effectiveness Considerations?
    Drummond M
    Value Health; 2016; 19(5):525-30. PubMed ID: 27565268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NICE, social values, and balancing objectivity and equity.
    Hill SR; Olson LG
    Pharmacoeconomics; 2014 Nov; 32(11):1039-41. PubMed ID: 25249201
    [No Abstract]   [Full Text] [Related]  

  • 36. A review of the use of health status measures in economic evaluation.
    Brazier J; Deverill M; Green C; Harper R; Booth A
    Health Technol Assess; 1999; 3(9):i-iv, 1-164. PubMed ID: 10392311
    [No Abstract]   [Full Text] [Related]  

  • 37. The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual.
    Angelis A; Harker M; Cairns J; Seo MK; Legood R; Miners A; Wiseman V; Chalkidou K; Grieve R; Briggs A
    Value Health; 2023 Oct; 26(10):1503-1509. PubMed ID: 37268059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Impact of Decision Makers' Constraints on the Outcome of Value of Information Analysis.
    Koffijberg H; Knies S; Janssen MP
    Value Health; 2018 Feb; 21(2):203-209. PubMed ID: 29477402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
    Carroll C; Houten R; Boland A; Kaltenthaler E; Dickson R
    Value Health; 2018 Mar; 21(3):341-350. PubMed ID: 29566842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020.
    Polak TB; Cucchi DGJ; Darrow JJ; Versteegh MM
    BMJ Open; 2022 Apr; 12(4):e058279. PubMed ID: 35396306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.